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ABSTRACT
We propose a statistical framework, named
genoCN, to simultaneously dissect copy number
states and genotypes using high-density SNP
(single nucleotide polymorphism) arrays. There are
at least two types of genomic DNA copy number
differences: copy number variations (CNVs) and
copy number aberrations (CNAs). While CNVs are
naturally occurring and inheritable, CNAs are
acquired somatic alterations most often observed
in tumor tissues only. CNVs tend to be short and
more sparsely located in the genome compared
with CNAs. GenoCN consists of two components,
genoCNV and genoCNA, designed for CNV and
CNA studies, respectively. In contrast to most exist-
ing methods, genoCN is more flexible in that the
model parameters are estimated from the data
instead of being decided a priori. GenoCNA also
incorporates two important strategies for CNA stu-
dies. First, the effects of tissue contamination are
explicitly modeled. Second, if SNP arrays are per-
formed for both tumor and normal tissues of one
individual, the genotype calls from normal tissue
are used to study CNAs in tumor tissue. We evalu-
ated genoCN by applications to 162 HapMap indi-
viduals and a brain tumor (glioblastoma) dataset
and showed that our method can successfully iden-
tify both types of copy number differences and
produce high-quality genotype calls.
INTRODUCTION
Several recent studies have documented the extensive
presence of inheritable copy number variations (CNVs)
in the human genome (1–8). Copy number aberrations
(CNAs), which are acquired somatic alterations, are
often observed in tumor tissues (9,10). In contrast to
CNVs, CNAs tend to be longer and occupy a signiﬁcant
proportion of the genome. In addition to the traditional
array CGH approach (11), CNVs or CNAs can also be
detected by SNP arrays, which typically have higher reso-
lution and are able to capture allele-speciﬁc information
(12). In this article, we propose a statistical framework to
simultaneously dissect copy number states and genotypes
within CNV/CNA regions. Currently, the two most fre-
quently used SNP array platforms are from Aﬀymetrix
(8) and Illumina (13). In this article, we focus on Illumina
SNP arrays, however, our method, accompanied with an
appropriate normalization and transformation of the raw
data,canalsobeappliedtoAﬀymetrixSNParrays.Adjust-
ments for CNV and CNA are also needed to ensure precise
genotype calls when using SNP arrays for genotyping.
Various methods have been proposed to study copy
number alterations. These methods can be classiﬁed
based on their input and output data. We ﬁrst brieﬂy
introduce diﬀerent types of input data. Denote the two
alleles of one SNP as A and B, respectively, and let X/Y
be the normalized intensities of allele A/B, i.e. allele-
speciﬁc copy number measurements. X and Y can be
transformed to a measure of overall copy number and a
measure of allelic contrast. For example, the outputs of
Illumina SNP arrays are Log R ratio (LRR) and B allele
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and allelic contrast measure, respectively (13). The calcu-
lation of LRR and BAF is elaborated at the beginning of
the ‘Method’ section.
First, segmentation methods such as circular binary seg-
mentation (14) and forward–backward fragment assem-
bling (FASeg) (15) have been applied to dissect copy
number states based on overall copy number measure-
ments (e.g. LRR). These methods are simple and robust,
but have the limitation that they cannot produce allele-
speciﬁc copy number estimates. A more advanced segmen-
tation method is proposed by Staaf et al. (16), which is
able to detect allelic imbalance and loss of heterozygosity
(LOH).
Second, model-based approaches such as CARAT (17)
and PLASQ (18) have been developed to identify CNAs in
tumor tissue based on the assumption that the relationship
between copy number and probe intensity is approxi-
mately linear on a log–log scale. The inputs are genotypes
in normal tissues and allele-speciﬁc copy number measure-
ments (i.e. X and Y) in both normal and tumor tissues.
The outputs are allele-speciﬁc copy number estimates in
tumor tissue. Speciﬁcally, a linear model in log–log scale is
build for each SNP based on the data from normal tissues,
and then the resulting model is used to predict the copy
number in tumor tissue. At the end, the results are further
smoothed across SNPs. One weakness of these approaches
is that the model parameters estimated from normal tissue
may not be appropriate for tumor tissue, for example, due
to normal tissue contamination. Normal tissue contami-
nation is inevitable in cancer studies and it may be due to
diﬀerent reasons. For example, normal tissue adjacent to
tumor tissue that is incompletely removed during the pro-
cess, and/or the presence of nontumor stromal cells and
immune cells, which are typically a part of every solid
tumors examined.
The third type of approach focuses on identifying LOH
together with qualitative copy number states (e.g. deletion,
normal and ampliﬁcation) in tumor tissue (19) or in gen-
eric situations (20). Their inputs include copy number
measurements and some prior knowledge regarding
the copy number and/or genotypes. Speciﬁcally, in
Yamamoto et al. (19), a genomic region of copy number
2 in tumor tissue needs to be known and the heterozygos-
ity of each SNP needs to be redeﬁned based on empirical
results. Scharpf et al. (20) proposed a hidden Markov
model (HMM) integrating observed heterozygosity
status and copy number measurements. Their method
enjoys the ability to exploit the conﬁdence scores of the
genotype calls. One shared limitation of these two meth-
ods is that the prior knowledge of the copy number and/or
genotype may not be available, or may be inaccurate in
CNV/CNA regions.
A recent paper (21) proposed a framework for inte-
grated study of genotype and copy number by analyzing
common and rare CNVs separately. Speciﬁcally, Korn
et al. (21) treated those common CNVs (>1% frequency
in the population) as copy number polymorphisms
(CNPs) with known locations as well as a few allele-
speciﬁc copy number states. Therefore the identiﬁcation
of common CNVs reduced to ‘genotyping’ the CNPs.
For the rare CNVs ( 1% frequency), they identiﬁed
copy number states within each sample by an HMM
using allele-speciﬁc copy number measurements. Then
the genotypes of each SNP within CNV regions are iden-
tiﬁed by a two dimensional clustering across individuals.
All the above methods are mainly designed for
Aﬀymetrix SNP arrays. For Illumina SNP arrays, two
HMM-based approaches, QuantiSNP (22) and
PennCNV (23), have been developed to identify copy
number states based on both LRR and BAF. Both
QuantiSNP and PennCNV are based on a HMM with
hidden states listed in Table 1. PennCNV assumes that
the mean value and SD of LRR and BAF for each
HMM state are known. QuantiSNP imposes some
common priors for the LRR/BAF parameters so that
only a few hyper-parameters need to be estimated. In
addition, PennCNV has an additional advantage that
family relationships can be utilized. However, both meth-
ods are not designed for CNA studies and do not provide
output on allele-speciﬁc information, such as genotypes.
Despite the successes of the aforementioned methods in
diﬀerent applications, some important issues remain to be
addressed, which motivated our study. First, as we men-
tioned previously, normal tissue contamination in tumors
occurs and complicates the determination of true tumor-
speciﬁc copy alterations of solid tumors, and as shown in
the ‘Results’ section, it may lead to signiﬁcant changes of
the data. However, no method has been designed to dis-
sect copy number and genotype calls within CNA regions
in the presence of normal tissue contamination. Although
both CARAT (17) and PLASQ (18) are able to dissect
allele-speciﬁc copy number states, and hence genotypes,
none of them has taken normal tissue contamination
into account. In addition, these two methods heavily
depend on the design of Aﬀymetrix SNP arrays, thus it
is not trivial to extend them to the data generated from
Illumina SNP arrays. Secondly, existing methods such as
QuantiSNP and PennCNV either assume that the model
parameters are known or impose some common priors.
These restrictions may be reasonable for CNV studies,
but they reduce the ﬂexibility of CNA studies. For exam-
ple, varying proportions of normal tissue contamination
across samples require sample-speciﬁc model parameters.
In this article, we propose a more sophisticated HMM-
based framework: genoCN. GenoCN consists of two com-
ponents: genoCNV and genoCNA, which are designed for
CNV and CNA studies, respectively. The input data are
LRR and BAF of each SNP. For CNA studies, the geno-
type calls of normal tissue (of the same patient) are an
optional input. The outputs are the posterior probabilities
Table 1. Six states of genoCNV
State Copy number Genotype
1 2 AA, AB, BB
2 2 AA, BB
3 0 Null
4 1 A, B
5 3 AAA, AAB, ABB, BBB
6 4 AAAA, AAAB, AABB, ABBB, BBBB
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parameter estimation scheme is developed so that those
HMM parameters are estimated from the data. The
HMMs for genoCNV and genoCNA are designed diﬀer-
ently to incorporate diﬀerent genotype classes in CNV and
CNA data as well as the eﬀects of tissue contamination
in CNA data. In addition, genoCNA is able to utilize
genotype calls from normal tissue to improve its robust-
ness and accuracy.
METHOD
Calculation of LRR and BAF
Recall that for each SNP, X and Y are the normalized
intensity measurements of allele A and B, respectively. X
and Y are ﬁrst transformed to be R=X+Y and
 =arctan(Y/X)/( /2) so that R measures the overall
copy number and   measures the allelic contrast. LRR is
deﬁned as log2(Robserved/Rexpected). If SNP arrays are
performed for both tumor and normal samples of the
same individual, we simply have Robserved=Rtumor and
Rexpected=Rnormal. Otherwise, Rexpected is computed by
linear interpolation of the canonical genotype cluster cen-
troids. The canonical genotype clusters are three clusters
corresponding to genotype AA, AB and BB on the scatter
plot of R versus   [Figure 1 of Peiﬀer et al. (13)].
The canonical genotype clusters for each SNP can be gen-
erated from all the samples in the study or from a set of
reference samples, such as HapMap samples. The BAF is
normalized  . Speciﬁcally,
BAF ¼
0i f  <  AA
0:5ð     AAÞ=ð AB    AAÞ if  AA    <  AB
0:5þ 0:5ð     ABÞ=ð BB    ABÞ if  AB    <  BB
1i f      BB
8
> > > <
> > > :
where  AA,  AB and  BB are the   values for the centroids
of the three canonical genotype clusters corresponding
AA, AB and BB, respectively. Based on the above for-
mula, BAF should be around 0, 0.5 and 1 for genotype
AA, AB and BB, respectively. If the BAF value of an SNP
is deviated away from these three values, it may indicate
copy number alterations. For example, a BAF value 0.33
may indicate a genotype of AAB.
Two continuous time HMMs with discrete states
We employ HMM to infer both copy number states and
genotypes from SNP array data. HMMs have been widely
used in speech recognition (24), and more recently in
DNA/protein sequence alignment (25). In those applica-
tions, the ‘time’ space of the Markov process is discrete.
For example, in DNA sequence studies, one time point is
just 1nt. Therefore, discrete time HMMs are used in these
studies. In the studies of SNP array data, ‘time’ is equiv-
alent to the genomic location. Because the data (DNA
allele intensities) are only observed at SNP probes and
the distances between adjacent SNP probes vary, we
employ continuous time HMM to model the transition
between adjacent probes. Two HMMs with diﬀerent
states are designed for CNV and CNA studies, which we
refer to as genoCNV and genoCNA, respectively.
Similar to the previous studies (22,23), genoCNV has
six states (Table 1). The State 2 is often referred to be
‘copy number neutral LOH’. It is a genomic aberration,
which may be due to uniparental disomy, mitotic recom-
bination events or deletion of one allele and subsequent
duplication of the remaining allele. LOH has been related
with cancer since losing one allele of a tumor suppressor
gene may lead to cancer genesis. Unlike the previous stu-
dies (22,23), we estimate the parameters from data instead
of ﬁxing them or imposing prior distributions. More
importantly, genoCNV dissects both copy number and
genotype calls, while the previous studies (22,23) only
output copy number state estimates.
Unlike genoCNV, genoCNA has nine states (Table 2).
For copy number 3 or 4, it is possible that one allele is
deleted ﬁrst before the other allele is ampliﬁed. States 6
and 8 correspond to this situation. State 7 is due to simul-
taneous ampliﬁcation of both alleles, and State 9 is due
to the ampliﬁcation of one allele twice. In addition, tissue
contamination leads to two extra genotype classes for
the states having only homozygous genotypes (States 2,
4, 6 and 8). For example, in a locus of hemizygous dele-
tions (loss of one allele) in tumor tissue, the remaining
allele could be either A (corresponding to AA or AB in
normal tissue) or B (corresponding to AB or BB in normal
tissue). With tissue contamination, the observed LRR and
BAF reﬂect the mixture distribution of (A, AA), (A, AB),
(B, AB) and (B, BB). Here we use underscore to indicate
that the genotype is from normal tissue contamination.
The expected LRR of these four mixtures are the same,
but closer to 0 compared with the LRR without normal
tissue contamination. This is because without normal
tissue contamination, the copy number is 1, and the
corresponding LRR is negative, denoted by b (b<0). In
contrast, the copy number within normal tissue is 2, thus
the corresponding LRR is  0. With normal tissue contam-
ination, the copy number is between 1 and 2, and thus the
LRR for the mixture is between b and 0. The expected
BAFs of (A, AA) and (B, BB) are still 0 and 1, respectively.
The BAFs of (A, AB) and (B, AB) are no longer 0 and 1.
Their exact values depend on the proportion of tissue
Table 2. Nine states of genoCNA
State Copy
number
Genotype
1 2 AA, AB, BB
2 2 AA, (AA, AB), (BB, AB), BB
3 0 Null
4 1 (A, AA), (A, AB), (B, AB), (B, BB)
5 3 (AAA, AA), (AAB, AB), (ABB, AB), (BBB, BB)
6 3 (AAA, AA), (AAA, AB), (BBB,AB), (BBB, BB)
7 4 (AAAA, AA), (AABB, AB), (BBBB, BB)
8 4 (AAAA, AA), (AAAA, AB), (BBBB, AB), (BBBB, BB)
9 4 (AAAA, AA), (AAAB, AB), (ABBB, AB), (BBBB, BB)
Genotype classes in parenthesis, such as (A, AB) are due to normal
tissue contamination of genotype A from tumor tissue and genotype
AB from normal tissue. Here we use underscore to indicate that the
genotype is from normal tissue contamination.
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or equivalently, two genotype classes.
Following the notations of Wang et al. (23), we use ri, bi
and zi to indicate the LRR, BAF, and the hidden state
at the i-th SNP probe, respectively. Assuming that the
LRR and BAF are independent given the underlying
states, the full likelihood is
pðr1;...;rL;b1;...;bLÞ
¼
X
z1
   
X
zL
pðz1Þ
Y L
i¼1
pðrijziÞ
Y L
i¼1
pðbijziÞ
Y L
i¼2
pðzijzi 1Þ
"#
:
1
If SNP arrays are performed in both tumor and normal
tissues of the same individual, we incorporate the geno-
type calls in normal tissue into genoCNA. Let gi be the
genotype of the i-th SNP in normal tissue, we have the
overall likelihood:
pðr1;...;rL;b1;...;bLjg1;...;gLÞ
¼
X
z1
   
X
zL
pðz1Þ
Y L
i¼1
pðrijziÞ
Y L
i¼1
pðbijzi;giÞ
Y L
i¼2
pðzijzi 1Þ
"#
:
2
The genotype in normal tissue is based on the assump-
tion that the copy number is 2, thus it can only be AA, AB
or BB; therefore it does not provide information of the
actual copy number in tumor tissue. This is why the like-
lihood of ri does not depend on gi. However, the genotype
in normal tissue restricts the genotype in tumor tissue. For
example, if the genotype in normal tissue is AA, then
either deletion or ampliﬁcation can only produce geno-
types of homozygous A. Speciﬁcally, Table 3 lists all the
possible correspondences between genotypes in normal
tissue and tumor tissue. We also allow a small probability
that those correspondences are violated, which could be
due to genotyping error in normal tissue.
The fulllikelihoods inEquations (1)and(2)includetran-
sition probabilities (p(zi|zi 1)) and the emission probabil-
ities of LRR (p(ri|zi)) and BAF (p(bi|zi)o rp(bi|zi, gi)). Some
SNP arrays incorporate some copy-number-only probes,
which only have one allele. For those probes, we discard
the BAF information, and only keep the emission proba-
bility of LRR and transition probability in the full likeli-
hood.Nextwediscusshowtoformulatetheseprobabilities.
Transition probability
For continuous time HMM, the transition probability
is evaluated according to time. pjk(t) p(s(w+t)=
k|s(w)=j) is the transition probability from state j to k
during time t, where s(w) and s(w+t) indicate states at
time w and w+t, respectively. An intensity matrix
 =( jk) is used to model the instantaneous transition
rate, where  jk=lim t!0pjk( t)/ t, j6¼k and  jj= 
P
k6¼j
 jk. The transition probability can be calculated by matrix
exponential: pjk(t)=exp(t ). However, matrix exponen-
tials are often diﬃcult to compute eﬃciently and reliably
(26). We bypass this problem by assuming that there is at
most one state transition between two adjacent SNP
probes. Under this assumption, no matrix exponential is
needed. This assumption is reasonable for high-density
SNP arrays, as the adjacent SNP probes are generally
close to each other. Occasionally, the distance between
two adjacent SNP probes is big (or in the extreme case, if
we consider two chromosomes), then we restart the
Markov process.
Let  j=
P
k6¼j  jk. The waiting time that the Markov
process stays at state j, denoted by Tj, follows an expo-
nential distribution with parameter  j. Let di be the dis-
tance between the (i 1)-th probe and the i-th probe.
pðzi ¼ jjzi 1 ¼ jÞ¼pðTj   diÞ¼expð  jdiÞ: 3
For a Markov process at time i and state j, once it leaves
state j, the transition probability to another state k
is ajk= jk/ j. In addition, Tj is independent with the des-
tination state k (27). Based on our assumption that ‘there
is at most one state transition between two adjacent
probes’, the transition probability from state j to k
(k6¼j)i s
pðzi ¼ kjzi 1 ¼ j;diÞ¼pðzi ¼ kjzi 1 ¼ jÞpðTj   diÞ
¼ ajkð1   expð  jdiÞÞ;
4
where
P
k6¼jajk=1.
Emission probability of LRR
Similar to the previous studies (22,23), we model the emis-
sion probability of LRR (denoted as r) by the mixture of a
uniform distribution and a normal distribution. Let  (r;
m,s) be the density function of normal distribution with
mean m and SD s.
pðrjzÞ¼ r;z
1
Rm
þð 1    r;zÞ ðr; r;z;  r;zÞ; 5
where the uniform distribution (with density 1/Rm) models
the background noise, the normal distribution with mean
mr,z and SD sr,z models the LRR signals of state z, and  r,z
is the mixture proportion of the uniform component.
We treat Rm as a known constant, which is simply the
length of LRR’s range.
Table 3. Correspondence between genotypes in normal tissue and tumor tissue
Normal HMM states and genotypes in tumor tissue
1 2 3 4 567 8 9
AA AA AA Null A AAA AAA AAAA AAAA AAAA
BB BB BB Null B BBB BBB BBBB BBBB BBBB
AB AB AA, BB Null A, B AAB, ABB AAA, BBB AABB AAAA, BBBB AAAB, ABBB
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We model BAF (denoted as b) by the mixture of a uniform
component for background noise and several (truncated)
normal components:
pðbjzÞ¼ b;zIð0 < b < 1Þ
þð 1    b;zÞ
X Hz
h¼1
wz;h ðb; z;hÞ
Ið0<b<1Þ ð0; z;hÞ
Iðb¼0Þ
  1    ð1; z;hÞ
   Iðb¼1Þ; 6
where  b,z is the mixture proportion of the uniform
component for state z, I(.) is the indicator function, Hz
indicates the total number of normal components of state
z, and wz,h is the weight of the h-th component.   and  
indicate normal density and cumulative normal distri-
bution, and  z,h={mb,z,h, sb,z,h} indicates the mean and
SD of the h-th normal component for state z. The geno-
type classes of one state are ordered by the number of B
alleles as shown in Tables 1 and 2.
Now we discuss the values of wz,h. The weight for State
3 (the null state with both alleles deleted) is 1 for either
genoCNV or genoCNA. Besides State 3, for genoCNV or
genoCNA without genotype from normal tissue, wz,h are
binomial probabilities based on the population frequencies
of the B alleles. For genoCNA with genotype from normal
tissue, we can reﬁne the weights wz,h according to the cor-
respondences in Table 3. First, if the genotype in normal
tissue is homozygous, the genotype in tumor tissue is also
homozygous for the same allele. Second, if the genotype in
normal tissue is heterozygous, BAF in tumor tissue follows
a mixture distribution with less components than in a gen-
eral situation (except state 2). In either case, there is a small
probability of exception, which can be attributed to factors
such as genotyping error. See the Supplementary Data for
the detailed formulation.
The parameters to be estimated
There are a large number of parameters to be estimated
for either genoCNV or genoCNA. We reduce the number
of parameters by some reasonable or obvious simpliﬁca-
tions. First, in either genoCNV or genoCNA, some states
share the same copy number and the same genotype, so
that the corresponding parameters can be estimated
jointly. For example, in genoCNA, States 7, 8 and 9
have the same copy number and they all share the geno-
type classes AAAA and BBBB. Second, mean values
of some normal components of BAF can be assumed as
constants. Speciﬁcally, for State 3, the null state with both
allele deleted, we assume mb,3,1=0.5. For the other states,
we assume mb,z,1=0 for genotypes of homozygous A allele
and mb,z, Hz=1.0 for genotypes of homozygous B allele.
For transition probability, we set  j as constant based
on prior knowledge/preference. Because the duration of
state j follows an exponential distribution with parameter
 j, the average duration, denoted as   Tj, equals to 1/ j.
Therefore,  j can be estimated by 1=   Tj. However,   Tj is dif-
ﬁcult to estimate because (i) state changes could occur at
any position between two adjacent probes, which we
cannot observe and (ii) even if we assume that state
changes always happen at SNP probes, the Baum–Welch
algorithm (24) for parameter estimation requires the pos-
terior probability that any segment arises from state j,
which is computationally infeasible because the number
of segments increases exponentially as the total length of
DNA sequence increases. Due to the above computational
diﬃculties, and also because  j can be treated as a tuning
parameter that determines the duration of state j,w e
choose to specify  j based on prior knowledge/preference.
Parameter and state posterior probability estimation
The ﬁnal maximum likelihood estimations (MLEs) of the
parameters can be obtained by an EM (Expectation–
Maximization) algorithm known as the Baum–Welch or
forward–backward algorithm (24), by numerical optimiza-
tion methods (28), or by MCMC (Markov chain Monte
Carlo) methods (29). Numerical optimization methods,
such as the Nelder–Mead method, become less reliable if
there are a large number of parameters, which is the case
in our study. The MCMC methods are computationally
demanding, especially for large-scale studies such as a
genome-wide dissection of CNVs/CNAs. Therefore we
employ the Baum–Welch algorithm to estimate the para-
meters. The estimation algorithm is brieﬂy described as
follows and the details are left in the Supplementary Data.
Let   be all the parameters to be estimated. First, given
^  , either initial values or estimates from the previous EM
step, we can calculate the posterior probability that probe
i is from state z, i.e.  ði;zÞ¼pðqi ¼ zjX; ^  Þ, where qi indi-
cates the state of probe i, and X indicates the observed
data. Furthermore, we can calculate the posterior proba-
bility that probe i is from state z and it belongs to a
particular genotype class, i.e.  ði;z;Nb;z;hÞ¼pðqi ¼
z;  i ¼ Nb;z;hjX; ^  Þ, where Zi=Nb,z,h indicates that probe
i belongs to the h-th genotype class of state z, and the
subscript b indicates this is the normal component for
BAF. With these posterior probability estimates, we can
re-estimate  . We iterate this procedure until the estimates
of   converges. By default, we use the convergence crite-
rion that for at least 10 iterations, the maximum change of
any parameter estimate is <0.002.
At the end, using the parameters at convergence, we can
estimate theposterior probabilities for each SNP belonging
to a particular copy number state or a genotype class.
These posterior probability estimates are our ﬁnal outputs.
The posterior probability of certain copy number is either
g(i,z) or the summation of g(i,z)’s of all the HMM states
corresponding to the same copy number. For example,
the copy numbers of States 1 and 2 are both 2, so
pðcopy number of the i-th; SNP is 2jX; ^  Þ¼ ði;1Þþ ði;2Þ:
Similarly, the posterior probability of certain genotype
class is the summation of all the corresponding g(i,z,
Nb,z,h)’s.
RESULTS
CNVs in HapMap individuals
To evaluate genoCNV, we applied it to study CNVs in
chromosome 1–22 of 162 HapMap individuals (30): 12
Nucleic Acids Research, 2009,Vol.37, No. 16 5369CEU parents–child trios, 17 YRI trios and 75 CHB+JPT
individuals. The data were generated using the Illumina
Human 610-Quad array. There are 600470 probes on
chromosome 1–22, among which 17931 ( 3%) are
copy-number-only probes. Five individuals had been
excluded due to unexpected chromosome-wide ampliﬁca-
tion or highly noisy array data. See the Supplementary
Data for details.
PennCNV (23) is a state-of-the-art CNV identiﬁcation
method that is speciﬁcally designed for Illumina SNP
arrays. We compared the results of genoCNV and
PennCNV by two diﬀerent approaches. First, we counted
the number of CNVs identiﬁed by either genoCNV or
PennCNV, and among them, the number/proportion of
CNVs that match the common CNVs reported in a
recent study by McCarroll et al. (8). Speciﬁcally, we say
a CNV matches another if the center of the former lies
within the latter and they have the same copy number
calls. The set of CNVs identiﬁed by McCarroll et al.i sa
reasonable standard to evaluate our method because they
identiﬁed CNVs using the same HapMap population and
their results have a good degree of agreement with other
existing data (8). As shown in Table 4, PennCNV (P) and
genoCNV (X) have comparable performances.
Second, using the family information of the 12 CEU
trios and the 17 YRI trios, we checked the number of
CNVs identiﬁed in the oﬀsprings that matched a CNV
identiﬁed in at least one parent. Because CNVs are inheri-
table, the number and proportion of CNVs shared
between parents and child are indirect, but reasonable
measures of the methods’ performances. For the 12
CEU trios, 480/474 CNVs are identiﬁed by genoCNV
and PennCNV, respectively, among which 194/206
match at least one CNV in the parents. For the 17 YRI
trios, 801/757 CNVs are identiﬁed by genoCNV and
PennCNV, respectively, among which 326/339 match at
least one CNV in the parents. See the Supplementary
Data for the number of matches per family.
In summary, overall genoCNV and PennCNV have
similar performances in terms of identifying CNVs in
these HapMap individuals. However, genoCNV provides
genotype calls in CNV regions while PennCNV does not.
The genotype calls can have important applications such
as studying the allele-speciﬁc eﬀects for gene expression
or other complex traits (see the ‘Discussion’ section for
details).
CNAs in brain tumors
Next, we sought to evaluate the performance of genoCNA
by applying it to a brain tumor dataset (Illumina Hap550
SNP arrays) from The Cancer Genome Atlas project
(TCGA) (31). We compared the results of genoCNA
and PennCNV to justify the strategies employed in
genoCNA. By default, PennCNV adjusts the LRR
values so that the median of LRR is 0, adjusts the BAF
values so that the median of those BAF values between
0.25 and 0.75 is 0.5, and suppresses the state of copy
number neutral LOH. In CNA studies, these adjustments
are not appropriate for the following reasons. (i) If a sig-
niﬁcant proportion of the genome is deleted or ampliﬁed,
the median of LRR is deviated from 0. (ii) Due to tissue
contamination, BAF distribution may have a mode <0.25
or >0.75. For example, the mixture (A, AB) corresponds
to one mode of the BAF distribution (recall the under-
score in AB indicates it is from normal tissue). Suppose
the proportion of normal tissue is 10%, then the propor-
tion of B allele is 1/11, which should correspond to a
model well <0.25, but >0. (iii) The state of copy
number neutral LOH is often of interest. Therefore, we
changed the default of PennCNV to skip median adjust-
ments for LRR/BAF and to keep the copy number neutral
LOH state.
CNV methods often fail in CNA studies. We ﬁrst demon-
strate that CNV methods often fail to identify CNA
regions. As shown in Figure 1, at the end of chromosome
5 of TCGA sample 02_0099, there are three CNA regions:
two hemizygous deletion regions separated by a region of
copy number neutral LOH. PennCNV fails to identify the
deletion regions. In contrast, genoCNA captures these
CNAs by employing genotypes from normal tissue and
explicitly modeling tissue contamination (Figure 1).
Figure 2 shows an example of ampliﬁcation. Due to
tissue contamination, the LRR in the ampliﬁed regions
is lower than expected, and hence the results of
PennCNV ﬂuctuate between copy numbers 2 and 3
(Figure 2). Note that these results should not be taken
as a criticism of PennCNV. Instead, they demonstrate
the diﬀerence between CNV and CNA studies, and the
methods designed for the former should not be used for
the latter without modiﬁcation.
One observation from Figure 1 is that the extra bands
of BAF resulting from tissue contamination have diﬀerent
mean values for mixtures (A, AB) and (B, AB) compared
with mixtures (AA, AB) and (BB, AB). This is expected
since CNA regions with larger copy number are less sen-
sitive to tissue contamination. For example, if the propor-
tion of contamination is 0.5, the B allele account for 1/3
and 1/4 of the intensity for (A, AB) and (AA, AB), respec-
tively. Another observation from Figures 1 and 2 is that
the BAF appears to be asymmetric around the expected
Table 4. Comparison of PennCNV (P) and genoCNV (X) by the number/proportion of CNVs that match the common CNVs reported by
McCarroll et al. (8)
36 CEU samples 51 YRI samples 75 CHB+JPT samples
PXPXP X
Total 1483 1444 2113 2289 2550 2440
Match (%) 479 (32) 478 (33) 889 (42) 886 (39) 997 (39) 961 (39)
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dye bias, and Staaf et al. (32) proposed a quantile normal-
ization method with an intensity transformation threshold
correction to handle this problem. In our genoCN frame-
work, all the parameters are estimated from data and are
already adapted to the asymmetry, thus a pre-normaliza-
tion is not necessary. The ﬁnal observation is that besides
inaccurate copy number calls, PennCNV also identiﬁes
many regions as copy number neutral LOH, which are
most likely false positives due to the diﬃculty to distin-
guish normal state and copy number neutral LOH. We
demonstrate in the next section how genoCNA overcomes
this problem.
Tissue contamination and genotype from normal
tissue. Unlike CNV methods (e.g. genoCNV or
PennCNV), genoCNA has two features: it explicitly
models the eﬀect of tissue contamination and it can utilize
genotype data from normal tissue of the same patient.
Figure 3 illustrates the diﬀerence made by these two fea-
tures in chromosome 13 of TCGA sample 02_0114. The
CNA patterns become cleaner after any one or both fea-
tures are employed. Speciﬁcally, short CNAs, especially
those regions of copy number neutral LOH, disappear.
GenoCN (either genoCNA or genoCNV) not only out-
puts the most likely copy number state and genotype call
for each SNP, but also the corresponding posterior
probabilities. The proportion of SNPs with high posterior
probabilities is a convenient measure of the success of the
algorithm. Examining the whole genome (more than
500000 SNPs) of TCGA sample 02_0114, we see that
the tissue contamination assumption and the usage of gen-
otype data from normal tissue lead to a small increase of
the proportion of high-conﬁdence copy number calls
(notice that the posterior probability of a copy number
state is the summation of the posterior probabilities of
all the corresponding HMM states. Thus elimination of
copy number neutral LOH as shown in Figure 3 does not
have big eﬀect on the posterior probability of copy
number state), but a signiﬁcant improvement of the pro-
portion of high-conﬁdence genotype calls (Table 5).
We further illustrate the LRR and BAF of the SNPs
with high-conﬁdence genotype calls (posterior probability
>0.95, Figure 4). The apparent clustering structure
in Figure 4 demonstrates the high accuracy of the geno-
type calls.
Empirical measurements of tumor purity. For each sample,
after dissecting the CNA regions and estimating the
parameters of LRR or BAF distributions, we can derive
an empirical measurement of tumor purity, i.e. the pro-
portion of tumor tissue in this sample. We denote this
proportion as pT, which can be estimated by expressing
the observed mean value of LRR/BAF as a function of pT
Figure 1. BAF and LRR of chromosome 5 of TCGA sample 02_0099, as well as the results of genoCNA and PennCNV. The y-axis of the results of
genoCNA/PennCNV corresponds to copy number. For a certain copy number, there may be diﬀerent states, which are distinguished by diﬀerent
colors. In this example, for copy number 2, ‘light blue’ and ‘dark blue’ indicate States 1 and 2 of genoCNA, respectively. When copy number
is 3, ‘orange’ and ‘dark red’ indicate States 5 and 6 of genoCNA, respectively.
Nucleic Acids Research, 2009,Vol.37, No. 16 5371and the expected LRR/BAF in pure tumor tissue. In this
article, we choose to use BAF to estimate pT because the
expected LRR in pure tumor tissue is not well deﬁned; in
contrast, the expected BAF is 0 or 1 for homozygous
genotypes, and 0.5 for heterozygous genotypes with
equal number of A and B alleles, regardless of the copy
number. Following Staaf et al. (16), assuming that BAF
can be approximated by the ratio of the number of B
alleles and the total number of alleles, we can estimate
the tumor purity from BAF data (see Section C of the
Supplementary Data for details).
We use 19 glioblastoma samples from TCGA study to
demonstrate the tumor purity estimation (Supplementary
Table C1). These samples are selected from 42 TCGA
samples produced by Stanford group, by examining the
LRR/BAF patterns to ensure they have diploid genomic
background, similar to the approach of Gardina et al.
(33). We ﬁrst estimate pT based on the BAF values from
CNA regions corresponding to States 2, 4 and 5 (Table 2),
which correspond to copy numbers 1, 2 and 3, respec-
tively. We denote these three sets of tumor purity esti-
mates as pT1, pT2 and pT3, respectively. Note for each
individual, pTj (j=1, 2, 3) is estimated only if there are
at least 500 SNPs belonging to the corresponding CNA
state with high conﬁdence (speciﬁcally, posterior probabil-
ity belonging to the CNA state >0.95). Consequently, pT1
and pT3 are estimated for all the 19 samples, but pT2 are
only estimated for eight samples. Figure 5a shows that pT1
and pT2 are highly consistent. Overall, pT1 and pT3 are also
consistent, although it appear that the estimates of pT3 are
more noisy (see Supplementary Figure C1). We illustrate
the distribution of pT1 in Figure 5b. More than half of
the samples have tumor purity <90%, and three of them
have tumor purity <60%.
For each tumor sample, top and bottom frozen sections
were stained with hematoxylin and eosin to determine the
percentage of tumor nuclei (31). We refer to the average
tumor percentage estimated from top and bottom sections
as clinically estimated tumor purity. Next we compare
our data-driven estimates of tumor purity with the clini-
cally estimated tumor purity (Supplementary Table C1).
The clinically estimated tumor purity is 100% for all
the 19 samples except for TCGA_02_0054 (95%),
TCGA_02_0099 (97.5%) and TCGA_02_0102 (97.5%).
The data-driven estimates of tumor purity for these
three samples are 53, 76, and 90%, respectively. The
apparent extra bands in the BAF plot when copy
number is 1 clearly indicate relatively low tumor purity
Figure 2. BAF and LRR of chromosome 17 of TCGA sample 02_0003, as well as the results of genoCNA and PennCNV.
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contradict the clinically estimated high tumor purity.
Therefore our results suggest a need for data-driven esti-
mates of tumor purity.
Parental-specific deletion/amplification. Given the copy
number state and the genotype call of each SNP within
a copy number altered region, an immediate follow-up
question is the parental origin of the deleted/ampliﬁed
DNA segment. For example, as shown in Figure 6a,
there is a deletion in TCGA sample 01_0007 at chromo-
some 17. GenoCNA can identify this CNA region and
estimate the genotype of each SNP within it. Then we
would ask whether the deleted segment is composed of
several smaller segments from either the paternal or
maternal copy of the chromosome or the entire deleted
region is from one copy of the chromosome. In order to
answer this question, we need to know the haplotypes in
normal tissue. While accurate haplotype information
is not available, we employed fastPHASE (34) to infer
the missing haplotypic phase. Because SNPs with homo-
zygous genotype are not informative for the haplotype
origin, we only examined the SNPs that are heterozygous
in normal tissue. Comparing the imputed haplotypic
phases in normal tissue with the estimated genotypes in
tumor tissue, most SNPs in this CNA region is from the
same haplotype, with a phase switch at the end of this
region (Figure 6). Note that this phase switch may reﬂect
a real genetic event or may be due to switch error of
Figure 3. BAF and LRR of chromosome 13 of TCGA sample 02_0114, as well as the results of genoCNA with three diﬀerent setups in terms
whether we assume tissue contamination and whether to use genotype from normal tissue. When copy number is 3, two colors ‘orange’ and ‘dark
red’ indicate States 5 and 6 of genoCNA, respectively.
Table 5. Proportion of the SNPs of TCGA sample 02_0114 that have
high posterior probabilities of copy number/genotype calls
Tissue
contamination
Genotype
from
normal tissue
Posterior probability
 0.8  0.9  0.95  0.99
No No 99.8/97.1 99.7/95.8 99.6/93.6 99.3/84.7
Yes No 99.9/97.9 99.8/97.0 99.7/95.3 99.5/87.8
Yes Yes 100.0/98.9 99.9/98.6 99.9/98.3 99.8/97.0
There are two numbers in each cell: a/b, where a is the proportion for
copy number states and b is the proportion for genotype states.
Nucleic Acids Research, 2009,Vol.37, No. 16 5373fastPHASE. We can be more conﬁdent about the haplo-
type if genetic data from other family members are avail-
able. Nevertheless, the results presented here clearly
demonstrate that at least the majority of the deletion is
from one parental allele. Given familiar inheritance data,
such parental-speciﬁc studies would provide more insights
about the genetic factors aﬀecting cancer susceptibility
and tumorigenesis.
Figure 4. Scatter plot of LRR and BAF for 547458 SNPs of TCGA sample 02_0114. These SNPs are from CNA regions (including copy number
neutral LOH) and the posterior probabilities of the most likely genotype class are >0.95.
Figure 5. (a) Comparison of the proportion of tumor sample (pT) estimated using mean BAF values when copy number is 1 [genotype (A, AB)]
and two [genotype (AA, AB)]. Each point corresponds to one sample. The diagonal line is y=x.( b) The distribution of pT, estimated using mean
BAF values when copy number is 1.
5374 Nucleic Acids Research, 2009, Vol. 37,No. 16Allelic bias in copy number-altered regions. Since genoCN
outputs the genotypes in CNV/CNA regions, it identiﬁes
the allelic bias of deletion/amplication for each individual.
An interesting question is whether some allelic bias is con-
served across individuals. Such allelic bias may be biolo-
gically more important than parental bias. The previous
publication by The Cancer Genome Atlas Research
Network (31) has shown that a large proportion of the
glioblastoma samples have deletion on chromosome 10.
To demonstrate the allelic bias study across individuals,
we examine the SNPs on chromosome 10 in 19 of the
brain tumor samples. We restrict our attention to the
301 SNPs with heterozygous genotype in normal tissue
and hemizygous deletion in tumor tissue for at least 11
of the 19 samples. Since the SNPs are heterozygous in
normal tissue, without allelic bias, either allele A or B
should be deleted with probability 0.5. We quantify the
allelic bias of the i-th SNP (across individuals) by a bino-
mial P-value: pbinom(min(ki, ni ki), ni, 0.5), where
pbinom denotes the cumulative distribution function of
binomial distribution, ni is the number of samples with
heterozygous genotype in normal tissue and hemizygous
deletion in tumor tissue, and ki is the number of cases
(among ni) where allele A is deleted. With a suggestive
P-value cut-oﬀ 0.0005, we identify three SNPs with
signiﬁcant allelic bias: rs10887549 (Chr10:87764377),
rs10788478 (Chr10:87797370) and rs10887554
(Chr10:87814218). They are all located within gene
GRID1, which encodes a subunit of glutamate receptor
channels. These channels mediate most of the fast excita-
tory synaptic transmission in the central nervous sys-
tem and play key roles in synaptic plasticity. Previous
association study has suggested that GRID1 is a candi-
date gene of schizophrenia (35). Here our allelic bias
study suggests a potential relation between GRID1 and
glioblastoma.
DISCUSSION
We propose a statistical framework to dissect both
CNVs or CNAs and estimate genotypes of the SNPs
within copy number-altered regions. In this article, we
mainly discussed the application for Illumina SNP
arrays. Accompanied with an appropriate normalization
and transformation method, our method can also be
applied to Aﬀymetrix SNP arrays. The normalization pro-
cedure of Aﬀymetrix SNP array data is itself an active
research topic; see Rigaill et al. (36) for an example.
In our empirical studies, genoCNV and PennCNV have
similar performances for identifying CNVs, but genoCNV
has the advantage of reporting genotype information
within CNV regions. In fact, genoCNV can be used to
estimate genotypes in the whole genome, not necessarily
in the CNV regions. The advantage compared with most
existing genotyping techniques (37–39) is that the geno-
type can be estimated within a single sample. One excep-
tion is the genotyping method developed by Giannoulatou
et al. (40), which can also be applied to a single sample,
although it is not designed to determine the genotype in
CNV regions.
For CNA studies, genoCNA has apparently better per-
formance than PennCNV due to diﬀerent model design,
data-driven parameter estimation, normal tissue contami-
nation consideration and incorporation of genotype data
from normal tissue. One remaining issue is to take into
account the possibility that the chromosomal background
may not be diploid (33). For those samples presented
in this article, we have examined the genome-wide LRR
and BAF data to make sure that the chromosomal back-
ground was diploid. We are actively developing a method
to dissect the ploidy status.
The availability of both copy number states and
genotype calls from CNV or CNA regions, provided
by genoCN, enables many important genetic studies.
Figure 6. Parental-speciﬁc deletion at chromosome 17 of TCGA sample 02_0007. (a) The BAF, LRR and copy number calls by genoCN around a
CNA (deletion) region. (b) In the BAF of the SNPs (of which the genotypes are heterozygous in normal tissue) in this CNA region. (c) This shows
which haplotype the remaining allele belongs to at each SNP.
Nucleic Acids Research, 2009,Vol.37, No. 16 5375For example, gene expression quantitative trait loci stu-
dies have attracted many research interests recently (41).
Previous studies have correlated gene expression with
copy number and genotype separately (42). However,
the joint study of copy number and genotype eﬀects on
gene expression has not been reported, at least partly due
to the lack of reliable genotype calls in copy number-
altered regions. The availability of genoCN, or similar
solutions in the future would greatly facilitate such joint
study, not only for gene expression traits, but also for
complex traits such as cancer susceptibility or even
causal relations that connect the genetic variation and
complex traits (43).
genoCN has been implemented in an R package, with
computational intensive parts written in C code. The R
package can be downloaded at http://www.bios.unc.edu
/ wsun/software.htm
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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